NRx Pharmaceuticals has announced the rescheduling of its second quarter 2025 financial results release to August 19, 2025. The company requires ad...
Emmaus Life Sciences, Inc., a biopharmaceutical company specializing in sickle cell disease treatment, has reported a significant decline in net re...
Kezar Life Sciences has reported its second quarter 2025 financial results, highlighting a decrease in cash reserves and operating expenses compare...
Emmaus Life Sciences, a biopharmaceutical company specializing in sickle cell disease treatment, has announced its financial results for the quarte...
NRx Pharmaceuticals has received FDA Fast Track designation for its drug NRX-100, aimed at treating suicidal ideation in patients with depression, ...
Denali Therapeutics Inc., a biopharmaceutical company specializing in treatments for neurodegenerative diseases, has released its Form 10-Q report ...
Senstar Technologies Corporation, a provider of security products and solutions, will release its financial results for the second quarter of 2025 ...
Circle, a stablecoin issuer, has reported a significant increase in revenue and reserve income in its first quarterly results since going public. T...
HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, has received final clearance from Florida's Agency for Health Care Administration (AH...